A graphene-Ag based near-infrared defined accurate anti-scarring strategy for ocular glaucoma surgery.
Yanan WangZikang XuWenchi LiWei WeiMengqi QinQun LiXuexia LiuXu ZhangXiaolei WangPublished in: Biomaterials science (2022)
Excessive fibrosis is the major factor in the failure of glaucoma filtration surgery. So far, the dominant approach for inhibiting fibrosis is the use of an antimetabolite drug, but the complications it causes, such as filtering bleb leakage, bacterial endophthalmitis and ocular hypotony, are also inevitable. Herein, a multifunctional anti-scarring platform (PVA@rGO-Ag/5-Fu) integrated with outstanding photothermal, antibacterial and drug delivery abilities is developed. PVA@rGO-Ag shows favorable biocompatibility as well as an accurate regional photothermal killing ability on both conjunctival fibroblasts and bacteria under 808 nm near-infrared (NIR) irradiation. Furthermore, PVA@rGO-Ag/5-Fu improves bleb survival rates and results in the satisfactory reduction of intraocular pressure (IOP) by decreasing the fibrous reaction in vivo . In summary, PVA@rGO-Ag/5-Fu has promising potential as an efficacious and safe anti-scarring agent for filtering surgery.
Keyphrases
- visible light
- drug delivery
- minimally invasive
- quantum dots
- coronary artery bypass
- reduced graphene oxide
- photodynamic therapy
- cancer therapy
- highly efficient
- drug release
- optic nerve
- surgical site infection
- high resolution
- signaling pathway
- risk assessment
- percutaneous coronary intervention
- high throughput
- climate change
- radiation induced
- silver nanoparticles
- radiation therapy
- single cell